

## EXERCISE PRICE DETERMINED FOR THE EXERCISE OF WARRANTS OF SERIES TO 6 IN ALLIGATOR BIOSCIENCE AB

Alligator Bioscience AB (publ) (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series TO 6 (the “warrants”) is SEK 0.40. The exercise period for the warrants begins on August 17, 2023, and runs up to and including August 31, 2023. The last day for trading in the warrants is August 29, 2023.

Alligator carried out a rights issue of units during April – May 2023 (the “Rights Issue”). Each unit issued in the Rights Issue consisted of one (1) ordinary share and one (1) warrant series TO 6. Eight (8) warrants of series TO 6 entitle the holder to subscribe for one (1) new ordinary share in the Company. If all warrants are exercised, Alligator will receive approximately SEK 20 million before issue costs.

The subscription price for the warrants was set at the higher of (i) SEK 0.40 and (ii) 70 percent of the volume-weighted average price for the Company's share on Nasdaq Stockholm during the period August 1, 2023 – August 14, 2023. 70 percent of the volume-weighted average price during the measurement period was below SEK 0.40 and thus the subscription price is SEK 0.40.

### Summary of instructions and important dates

Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise at latest on August 31, 2023. Warrants that have not been exercised on or before August 31, 2023, expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including August 29, 2023.

### Detailed information and instructions for subscription

#### *Exercise of nominee-registered warrants*

Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before August 31, 2023, as different nominees have different processing times.

**PRESS RELEASE**

15 August 2023 08:00:00 CEST

*Exercise of directly registered warrants*

Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Aktieinvest FK, no later than August 31, 2023.

The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites ([www.alligatorbioscience.com](http://www.alligatorbioscience.com), [www.aktieinvest.se](http://www.aktieinvest.se), [www.redeye.se](http://www.redeye.se)). Please note that payment for the new shares must be received by Aktieinvest no later than August 31, 2023, in accordance with the instructions on the application form.

**Trading in TO 6**

Holders who do not wish to exercise their warrants may sell them on Nasdaq Stockholm. The warrants are traded up to and including August 29, 2023, under the short name ATORX TO 6 and with ISIN code SE0020179653. Warrants that are not exercised on August 31, 2023, at the latest will expire without value.

**Outcome and delivery of new shares**

The outcome of the exercise of warrants will be published via a press release on or around September 4, 2023. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into ordinary shares in Alligator.

**Number of warrants and possible proceeds**

Upon full utilization of all 402,990,941 warrants series TO 6, the share capital will increase by a maximum of SEK 3,223,927.488 to SEK 43,193,570.304 through the issuance of a maximum of 50,373,867 new ordinary shares, resulting in that the total number of shares in the Company will increase from 624,525,669 to 674,899,536, whereof 673,949,686 are ordinary shares and 949,850 series C shares. Upon full utilization of all warrants series TO 6, the dilution of the ordinary shares amounts to approximately 7.5 per cent. The total number of votes in the Company will, following full utilization of all warrants series TO 6, amount to 674,044,671.

**PRESS RELEASE**

15 August 2023 08:00:00 CEST



If all warrants are exercised, Alligator will receive approximately SEK 20 million before issue costs.

**Complete terms and conditions for the warrants**

Complete terms and conditions for the warrants are available on the Company's website, [www.alligatorbioscience.com](http://www.alligatorbioscience.com).

**Advisers**

DNB Markets, a part of DNB Bank ASA, Sweden Branch and Redeye AB act as Joint Global Coordinators in connection with the Rights Issue. Setterwalls Advokatbyrå AB acts as legal adviser and Aktieinvest FK AB acts as the issuing agent in connection with the Rights Issue.

**For further information, please contact:**

---

Søren Bregenholt, CEO

E-mail: [soren.bregenholt@alligatorbioscience.com](mailto:soren.bregenholt@alligatorbioscience.com)

Phone: +46 (0) 46 540 82 00

LifeSci Advisors

Investor Relations

Guillaume van Renterghem

E-mail: [gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)

Phone: +41 (0) 76 735 01 31

**About Alligator Bioscience**

---

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit [alligatorbioscience.com](http://alligatorbioscience.com).

**PRESS RELEASE**

15 August 2023 08:00:00 CEST



## **Important information**

---

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Alligator. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Alligator has only been made through the prospectus published by Alligator on April 26, 2023, and through the supplement prospectuses published by Alligator on May 9, May 12, and May 24, 2023. The prospectuses have been approved and registered by the Swedish Financial Supervisory Authority and have been published on the Company's website, [www.alligatorbioscience.com](http://www.alligatorbioscience.com).

## **Attachments**

---

**Exercise price determined for the exercise of warrants of series TO 6 in Alligator Bioscience AB**